Maxpro Capital Acquisition (JMAC) Competitors $6.40 -0.16 (-2.44%) As of 04/28/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock JMAC vs. ATYR, ATAI, RNAC, MBX, PVLA, AURA, CMPX, PHAT, CYRX, and AQSTShould you be buying Maxpro Capital Acquisition stock or one of its competitors? The main competitors of Maxpro Capital Acquisition include Atyr PHARMA (ATYR), Atai Life Sciences (ATAI), Cartesian Therapeutics (RNAC), MBX Biosciences (MBX), Palvella Therapeutics (PVLA), Aura Biosciences (AURA), Compass Therapeutics (CMPX), Phathom Pharmaceuticals (PHAT), Cryoport (CYRX), and Aquestive Therapeutics (AQST). These companies are all part of the "pharmaceutical products" industry. Maxpro Capital Acquisition vs. Atyr PHARMA Atai Life Sciences Cartesian Therapeutics MBX Biosciences Palvella Therapeutics Aura Biosciences Compass Therapeutics Phathom Pharmaceuticals Cryoport Aquestive Therapeutics Maxpro Capital Acquisition (NASDAQ:JMAC) and Atyr PHARMA (NASDAQ:ATYR) are both small-cap manufacturing companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, community ranking, analyst recommendations, profitability, dividends, valuation and earnings. Does the MarketBeat Community favor JMAC or ATYR? Atyr PHARMA received 13 more outperform votes than Maxpro Capital Acquisition when rated by MarketBeat users. CompanyUnderperformOutperformMaxpro Capital AcquisitionN/AN/AAtyr PHARMAOutperform Votes13100.00% Underperform VotesNo Votes Do insiders and institutionals hold more shares of JMAC or ATYR? 73.2% of Maxpro Capital Acquisition shares are held by institutional investors. Comparatively, 61.7% of Atyr PHARMA shares are held by institutional investors. 19.3% of Maxpro Capital Acquisition shares are held by company insiders. Comparatively, 3.7% of Atyr PHARMA shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media prefer JMAC or ATYR? In the previous week, Atyr PHARMA had 7 more articles in the media than Maxpro Capital Acquisition. MarketBeat recorded 7 mentions for Atyr PHARMA and 0 mentions for Maxpro Capital Acquisition. Atyr PHARMA's average media sentiment score of 0.84 beat Maxpro Capital Acquisition's score of 0.00 indicating that Atyr PHARMA is being referred to more favorably in the news media. Company Overall Sentiment Maxpro Capital Acquisition Neutral Atyr PHARMA Positive Do analysts recommend JMAC or ATYR? Atyr PHARMA has a consensus price target of $18.60, indicating a potential upside of 436.02%. Given Atyr PHARMA's stronger consensus rating and higher probable upside, analysts clearly believe Atyr PHARMA is more favorable than Maxpro Capital Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maxpro Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Atyr PHARMA 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Which has preferable valuation and earnings, JMAC or ATYR? Maxpro Capital Acquisition has higher earnings, but lower revenue than Atyr PHARMA. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMaxpro Capital AcquisitionN/AN/AN/AN/AN/AAtyr PHARMA$235K1,312.09-$50.39M-$0.87-3.99 Which has more risk & volatility, JMAC or ATYR? Maxpro Capital Acquisition has a beta of 0.01, meaning that its stock price is 99% less volatile than the S&P 500. Comparatively, Atyr PHARMA has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500. Is JMAC or ATYR more profitable? Maxpro Capital Acquisition's return on equity of 0.00% beat Atyr PHARMA's return on equity.Company Net Margins Return on Equity Return on Assets Maxpro Capital AcquisitionN/A N/A N/A Atyr PHARMA N/A -79.44%-59.16% SummaryAtyr PHARMA beats Maxpro Capital Acquisition on 9 of the 13 factors compared between the two stocks. Get Maxpro Capital Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for JMAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JMAC vs. The Competition Export to ExcelMetricMaxpro Capital AcquisitionHolding Offices IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$85.94M$475.67M$2.02B$7.83BDividend YieldN/A7.74%2.70%4.22%P/E RatioN/A2.4122.4718.48Price / SalesN/A55.0660.49103.59Price / CashN/A69.0151.7234.62Price / BookN/A3.682.004.25Net IncomeN/A$35.22M-$333.48M$248.23M7 Day Performance8.84%1.71%0.80%0.89%1 Month Performance-15.90%3.42%-0.84%3.53%1 Year Performance1,402.35%24.13%8.07%5.08% Maxpro Capital Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JMACMaxpro Capital AcquisitionN/A$6.40-2.4%N/A+1,354.5%$85.94MN/A0.002,021Gap UpATYRAtyr PHARMA2.3999 of 5 stars$3.52+1.4%$18.60+428.4%N/A$312.78M$235,000.00-3.7453Short Interest ↑News CoverageGap UpATAIAtai Life Sciences2.6737 of 5 stars$1.52+3.4%$10.50+590.8%-24.2%$303.66M$308,000.00-1.8880Positive NewsRNACCartesian Therapeutics1.9551 of 5 stars$11.63+3.3%$42.67+266.9%-45.6%$301.30M$38.91M-0.2264Upcoming EarningsGap DownMBXMBX Biosciences2.4915 of 5 stars$8.99+4.1%$37.50+317.1%N/A$300.48MN/A0.0036PVLAPalvella Therapeutics3.4142 of 5 stars$26.56-1.3%$44.43+67.3%N/A$292.67M$42.81M-2.20N/AAnalyst ForecastAURAAura Biosciences2.3447 of 5 stars$5.76+0.9%$22.75+295.0%-21.2%$289.30MN/A-3.3350Upcoming EarningsShort Interest ↑Positive NewsGap DownCMPXCompass Therapeutics3.3847 of 5 stars$2.07+4.5%$13.38+546.1%+29.2%$286.25M$850,000.00-5.5920Analyst ForecastShort Interest ↑PHATPhathom Pharmaceuticals4.0385 of 5 stars$4.02+1.5%$21.83+443.1%-52.5%$279.94M$55.25M-0.71110Positive NewsCYRXCryoport2.3918 of 5 stars$5.59+0.5%$11.67+108.7%-65.5%$279.00M$228.39M-1.651,020Gap DownAQSTAquestive Therapeutics1.5117 of 5 stars$2.82+2.5%$10.67+278.3%-13.1%$278.82M$57.56M-6.27160Upcoming Earnings Related Companies and Tools Related Companies ATYR Competitors ATAI Competitors RNAC Competitors MBX Competitors PVLA Competitors AURA Competitors CMPX Competitors PHAT Competitors CYRX Competitors AQST Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:JMAC) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maxpro Capital Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maxpro Capital Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy JMAC Stock Free JMAC Stock Alerts